GX1.F Marker Therapeutics, Inc.

Healthcare Biotechnology Frankfurt Exchange
0.7100 EUR
Close of Nov 12, 2026
0.6450 1.72
Market cap
EUR 11.8M
P/E
-
P/B
1.23x
ROE
-82.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is GX1.F undervalued?

Graham number

The Graham number of Marker Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Marker Therapeutics, Inc. fundamental analysis

No fundamental analysis for Marker Therapeutics, Inc. yet.

Marker Therapeutics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601…

Full company profile